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Abstract The viral determinants governing the varied
neuropathogenicity of different West Nile virus (WNV)
strains are poorly understood. Here, we generated an
infectious clone (WNV-MADIC) of the non-pathogenic
strain WNV-MAD78 and compared its replication to that
of parental WNV-MAD78 and a WNV-MAD78 infectious
clone (WNV-MADTX-UTRs) containing the 50 and 30
untranslated regions (UTRs) of the pathogenic strain
WNV-TX. All three viruses replicated at similar rates and
caused similar lethality in mice. Thus, the infectious clone
is indistinguishable from parental virus in replication and
neurovirulence, and the UTRs alone do not account for the
increased virulence of WNV-TX compared to WNV-
MAD78.
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West Nile virus (WNV) is a member of the genus Flavi-
virus, family Flaviviridae. In Africa, Asia, and the Middle
East, WNV is endemic, and infection is primarily asymp-
tomatic or associated with a mild febrile illness known as
WN fever. However, recent outbreaks of WNV in the
western hemisphere have occurred with a significantly
higher incidence of severe neurological disease [1–5]. The
viral determinants responsible for the increased virulence
of these emerging WNV strains are poorly understood.
The naturally occurring diversity in the neuropathoge-
nicity among strains of WNV provides an excellent model
system to define virulence determinants of emergent
strains. To facilitate comparative pathogenicity studies, we
generated a complete full-length infectious clone of the
lineage 2 African isolate WNV-MAD78. Since WNV-
MAD78 is non-pathogenic in mice when inoculated in the
periphery [6, 7], it is a useful strain for comparison studies
with pathogenic lineage 1 strains such as WNV-NY99 or
WNV-TX02, for which infectious clones are also available.
Although the sequence of the first 10,866 nucleotides,
representing nearly the entire genome, of WNV-MAD78
was reported previously (accession DQ176636), the precise
length and sequence of the 30 end of the genome was not
determined. Therefore, we sequenced the 30 end of WNV-
MAD78 RNA extracted from infected A549 cells. TRIzol
(Invitrogen)-extracted RNA was treated with Terminator
Exonuclease (Epicentre) to selectively remove rRNA.
Since the WNV genome lacks a polyA tail, the extracted
RNA was polyadenylated with polyA polymerase (NEB)
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and then used as a template for reverse transcription (RT)
with an oligo-dT primer. The 30 end of the resulting cDNA
was PCR-amplified using the oligo-dT primer and a sense
primer corresponding to position 10743 within the WNV-
MAD78 genome. Sequence analysis identified 20 nucleo-
tides immediately adjacent to the added polyA nucleotides
that aligned with the 30 end of another lineage 2 strain of
WNV, WNV-956, suggesting that this sequence repre-
sented the exact 30 end of WNV-MAD78. To confirm the
sequence of the WNV-MAD78 30UTR, we repeated the
amplification of this region using the 10743 primer and an
antisense primer complimentary to the exact 30 end of the
WNV-MAD78 genome. Sequence analysis of the resulting
RT-PCR product identified a total of 97 nucleotides that
were not reported previously (Fig. 1a and accession num-
ber KJ909513). Alignment of the complete 30 UTR
sequence of WNV-MAD78 with that of other WNV strains
indicated that the WNV-MAD78 30 UTR diverges from
most lineage 1 and 2 strains (Fig. 1b). In contrast, the
WNV-MAD78 50UTR is highly conserved (Fig. 1b).
To generate a full-length infectious clone of WNV-
MAD78, we utilized the strategy outlined in Fig. 1c. First,
total RNA extracted from WNV-MAD78-infected Vero
cells was used as template for RT-PCR to generate eight
WNV-MAD78 cDNAs spanning the entire virus genome
(Fig. 1c, Stage 1). During PCR, an MluI restriction site
followed by the T7 promoter was inserted immediately
upstream of the 50 end of the genome (Fig. 1d). Several
other restriction sites were engineered at various locations
within the cDNAs to facilitate cloning but were not
incorporated into the final construct. Additionally, a NotI
restriction site was inserted at the 30 end of the genome
bFig. 1 Generation of a WNV-MAD78 infectious clone. (a) Scale
representation of WNV-MAD78. The last 97 nucleotides of the
genome, representing the additional portion sequenced here, are
indicated. (b) Percent identity of the 50 and 30 UTRs among WNV
strains. Sequences were downloaded from GenBank, and ClustalW
Alignment was performed with MacVector version 10.0.2 using the
entire UTR sequences. Values represent percent identities among
strains for the 30 UTR (bold text) or 50 UTR (regular text). The strains
used (with accession numbers indicated in parentheses) are as
follows: AUS60 (GQ851602), AUS91 (GQ851603), CO03
(DQ164203), TX02 (DQ164198), NY-3356 (AF404756), NY99
(AY842931), ROM97 (AF260969), ITA98 (AF404757), ETH76
(AY603654), EG101 (EU081844), IND68 (EU249803), MAD78
(DQ176636), CYP68 (GQ903680), WNV-956 (NC_001563), Sara-
fend (AY688948), CAR82 (DQ318020), SA58 (EF429200), SA89
(EF429197), and SEN90 (DQ318019). Strains 1 to 11 are lineage 1
and strains 12 to 19 are lineage 2. (c) Construction of the infectious
clone. RT-PCR was carried out on parental WNV-MAD78 RNA to
generate the eight cDNAs shown in Stage 1. Nucleotide boundaries
are numbered based on parental WNV-MAD78. Restriction sites
inserted during RT-PCR, which are not present in the genome, are
indicated (*), and those shown in gray were not present in the final
full-length construct. In Stage 2, the indicated fragments were
subcloned into the four plasmids indicated (Plasmid 1, pWSK29 [9];
Plasmid 2, pEGFP (Clonetech); Plasmid 3, pBKSM (Stratagene);
Plasmid 4, pWSK129 [9]). In Stage 3, the WNV-MAD78 regions of
Plasmids 1–4 were combined in the order indicated to generate the
full-length WNV-MADIC. Arrows indicate restriction digests.
(d) Annotated sequence of WNV-MADIC ends. On the left, the
sequence and location of the T7 promoter (white box) relative to the
WNV 50UTR (grey box) is indicated. The arrow indicates the site of
transcription initiation. On the right, the placement of the NotI site
(underlined nucleotides) at the end of the WNV 30 UTR (grey box) is
shown, with an arrow representing the position of endonuclease
cleavage. (e) Table of sequence differences between WNV-MADIC
and parental WNV-MAD78. Differences between our WNV-MAD78
stock, the recovered WNV-MADIC virus, the WNV-MADIC plasmid,
and the published WNV-MAD78 GenBank sequence (accession
DQ176636) are indicated
a b
Fig. 2 WNV-MADIC displays similar biological properties to paren-
tal WNV-MAD78. (a) Vero cells were inoculated with WNV-
MAD78 or WNV-MADIC (MOI = 0.05). Culture supernatants were
collected at the indicated times and the concentration of virus
was determined by plaque assay on Vero cells. Values represent the
average number of plaque-forming units (PFU) per mL of supernatant
(?/- standard deviation) from three independent experiments.
(b) Eight- to twelve-week-old C57BL/6 or Ifnar -/- mice were
infected with WNV-MAD78 or WNV-MADIC (n = 7) by subcuta-
neous injection of 100 PFU into the left rear footpad. Mice were
monitored daily and euthanized when body weight loss was[20 % or
they reached clinical scores of 4 or above (1, no paresis; 2, mild
paresis; 3, frank paresis; 4, severe paresis; 5, true paresis; 6,
moribund)
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(Fig. 1d). Each cDNA was blunt-end ligated into the
cloning vector pVL-blunt (a kind gift from Vincent Lee)
[8]. In Stage 2, the eight WNV fragments were subcloned
as indicated in Fig. 1c to generate four plasmids encoding
the entire genome. The full-length infectious clone
(pWNV-MADIC; accession number KJ909514) was gen-
erated by assembling the four WNV segments into the
very-low-copy plasmid pWSK29 [9] as outlined in Fig. 1c,
Stage 3. Sequencing of the final full-length construct
identified four silent mutations compared to the previously
published WNV-MAD78 sequence (Fig. 1e). To determine
if these mutations were introduced during the cloning
process, we sequenced the corresponding regions of our
WNV-MAD78 stock. Of the four mutations noted, three
were present in our WNV-MAD78 stock (Fig. 1e), indi-
cating that only one (T5339C) arose during the cloning
process.
To generate virus, linear pWNV-MADIC was used as
template for in vitro transcription, and 12 lg of the
resulting RNA was used to transfect 1 9 106 Vero cells
using the Neon Transfection System (Invitrogen) set to
the following conditions: 1150 V, 20 ms, and 2 pulses.
After seven days, culture supernatant containing WNV-
MADIC was collected and subsequently passaged once in
Vero cells to generate a working stock. The presence of a
cytosine nucleotide at position 5339 within the recovered
virus (Fig. 1e) confirmed that it was WNV-MADIC and not
parental WNV-MAD78.
To assess the biological properties of WNV-MADIC, we
compared the growth kinetics of the recovered virus to that
of the parental strain. Vero cells were infected with WNV-
MAD78 or WNV-MADIC and infectious particle produc-
tion assessed by plaque assay (Fig. 2a). Similar levels of








(a-c) A549 (a) (MOI = 0.05),
HBCA (b) (MOI = 0.01), or





collected and titers determined
as in Fig. 2(a). (d) Vero
monolayers were infected with
*50 pfu of WNV-MAD78,
WNV-MADIC, or WNV-
MADTX-UTRs. After 1 h,
inoculums were removed and a
0.9 % agarose-media overlay
was added. After 7 days, the
monolayers were fixed with 4 %
formaldehyde and stained with
crystal violet. (e) Four-week-old
Swiss Webster mice were
inoculated intracranially with
10 pfu of WNV-MAD78
(n = 20), WNV-MADIC
(n = 20), or WNV-
MADTX-UTRs (n = 20) or mock
inoculated (n = 10) with 20 lL
of PBS. Mice were monitored
daily and euthanized when body
weight loss was [20 % or
clinical scores indicated severe
disease
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levels occurring at 48 h after infection for both viruses
(Fig. 2a). Moreover, plaques for both viruses developed at
similar rates on Vero cells and were visible at 6 days post-
inoculation. To assess virulence, wild-type C57BL/6 and
interferon receptor knockout (Ifnar-/-) mice, which are
resistant and highly susceptible, respectively, to WNV-
MAD78 [7], were inoculated subcutaneously with 100 PFU
of WNV-MAD78 or WNV-MADIC (Fig. 2b). No differ-
ences in survival were observed. In wild-type mice, neither
strain caused mortality or weight loss, though one mouse
inoculated with WNV-MADIC showed mild signs of dis-
ease. In contrast, in the absence of IFN signaling, infection
with either strain was 100 % lethal. Thus, the virus
recovered from the infectious clone was indistinguishable
from the parental strain.
Recently, Suthar et al. generated a similar infectious
clone, herein referred to as WNV-MADTX-UTRs, which
contains the 50 and 30 UTRs of a virulent WNV strain,
WNV-TX [10]. The WNV-TX UTRs have notable differ-
ences from those of WNV-MAD78. Within the 50 UTR,
WNV-TX contains an extra adenosine at position 51, and
the WNV-TX 30UTR is 78 nucleotides longer and shares
only 73.2 % sequence identity with that of WNV-MAD78
(Fig. 1b). Specific sequences and structural folds within the
UTRs are critical for WNV replication [11–15], and pre-
vious work suggests that the UTRs are virulence determi-
nants [16]. Thus, sequence differences among the UTRs of
various WNV strains may alter the structure and function
of these regions and thereby influence the pathogenicity of
the resulting virus. To assess the effect of the TX-UTRs on
WNV-MAD78 fitness, we compared WNV-MAD78,
WNV-MADIC, and WNV-MADTX-UTRs replication in
A549 cells, human brain cortical astrocytes (HBCAs), and
C6/36 cells, models for WNV infection within the
periphery, the neurovascular unit, and the mosquito vector,
respectively. In all cell types, similar titers were observed
for all three viruses throughout the infection (Fig. 3a-c),
consistent with the initial characterization of WNV-
MADTX-UTRs within A549 cells [10]. Thus, the TX-UTRs
are neither beneficial nor detrimental to WNV-MAD78
replication in vitro. However, we consistently observed
that WNV-MADTX-UTRs plaques on Vero cells were larger
than those of WNV-MADIC or parental WNV-MAD78
(Fig. 3d), suggesting that the presence of TX-UTRs may
marginally enhance viral spread in some mammalian cells.
When inoculated in the periphery, parental WNV-
MAD78 and WNV-MADTX-UTRs are completely avirulent
in mice [10]. In contrast, approximately 60 % of mice
inoculated intracranially with parental WNV-MAD78
succumb to infection [17], making intracranial (IC) inoc-
ulation a good model for assessing virulence. To determine
if the WNV-TX UTRs affected WNV-MAD78 virulence,
we compared WNV-MAD78, WNV-MADIC, and WNV-
MADTX-UTRs in 4–week-old outbred Swiss Webster mice
(Harlan Laboratories) inoculated intracranially with 10 pfu
of virus or a sham PBS control. All viruses exhibited
similar lethality (Fig. 3e, p = 0.766), with 80–90 % of
infected animals succumbing to infection by 9 days after
inoculation. Morbidity correlated directly with mortality,
and no animals that lost weight or showed signs of disease
recovered (data not shown). Thus, the virulence phenotypes
of the infectious clones are indistinguishable from each
other and from that of parental WNV-MAD78.
In summary, we have generated an infectious WNV-
MAD78 clone (WNV-MADIC) that contains the authentic
UTRs of the viral RNA and is indistinguishable from
parental WNV-MAD78 in replication and neurovirulence.
Replacing the WNV-MAD78 UTRs with those of a path-
ogenic strain of WNV had no effect on the biological
phenotype of WNV-MAD78. This finding is consistent
with a study of another low-pathogenicity WNV strain,
Kunjin virus, in which replacing both the Kunjin UTRs
with those of WNV-NY did not enhance virulence in mice
[16], though replacing the 50 UTR alone did increase
pathogenicity. Thus, divergence among the UTRs of vari-
ous WNV strains may not be a determining factor in vir-
ulence, as long as they are maintained as a cognate pair.
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